AP
EW icon

Antipodes Partners’s Edwards Lifesciences EW Stock Holding History

Antipodes Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.3K Buy
+379
New +$31.7K ﹤0.01% 122

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Antipodes Partners's EW Position: Q2 2026 in Review

Antipodes Partners opened a new position in Edwards Lifesciences (EW) in Q2 2026: 379 shares worth $34.3K. The stake represents ﹤0.01% of the portfolio and ranks #122 among its holdings.

1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Antipodes Partners held 379 shares of Edwards Lifesciences worth $34.3K as of Q2 2026.
  • Edwards Lifesciences was a new Antipodes Partners position in Q2 2026.
  • Edwards Lifesciences made up ﹤0.01% of Antipodes Partners's portfolio in Q2 2026, its #122 holding.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.